Sermorelin after 3 months: separating real results from hype

What did @dalmadoesivy actually say?

The creator describes three months on sermorelin, reporting hitting a "target weight" in month one, improved muscle definition in month two, and better sleep, focus, and energy by month three. She credits the peptide with stimulating the body's own growth hormone production, cites Andrew Huberman as a reference point, and recommends working with a licensed provider. She's transparent that results weren't dramatic or overnight.

She also flags that she reduced alcohol use because you're "not supposed to mix those," and closes by saying her protocol was prescribed by a physician through IVRX. That last part matters, and we'll come back to it.

Does the science back this up?

Sermorelin is a growth hormone-releasing hormone (GHRH) analog. The basic mechanism is real: it stimulates the pituitary gland to secrete growth hormone endogenously, which is meaningfully different from injecting synthetic HGH directly. That distinction is pharmacologically legitimate.

On sleep: growth hormone secretion is tightly linked to slow-wave sleep. Walker et al. (2008, Sleep Medicine Reviews) established that GH pulses occur predominantly during deep sleep stages, so a compound that modestly elevates GH could plausibly support sleep architecture. The creator's claim about "deeper sleep" is consistent with the biology, though she has no polysomnography data to back her personal report.

On body composition: a 2006 Rudman-era follow-up and more recent work by Sigalos and Pastuszak (2018, Sexual Medicine Reviews) found GHRH analogs produced modest reductions in fat mass and modest lean mass gains in adults with GH deficiency, not healthy young adults. The effect size in non-deficient populations is much smaller than influencer content typically implies.

On focus and cognitive performance: this is the weakest link scientifically. There is no direct clinical trial showing sermorelin improves cognitive function in healthy adults. Sleep quality improvements may produce downstream cognitive benefits, but that is indirect and speculative.

What did they get wrong (or right)?

She gets partial credit for the mechanism. Calling sermorelin something that "signals your body to produce more of its own growth hormone" is a reasonable lay explanation. It's more accurate than creators who conflate sermorelin with synthetic HGH or peptide stacks like CJC-1295/ipamorelin, which work differently.

She gets the "long game" framing right. Anyone claiming rapid transformation from sermorelin is selling something. The peptide works through pulsatile GH release, which takes weeks to months to shift body composition measurably, and the effects are modest in people who don't have documented GH deficiency.

What she gets wrong: the cortisol angle is muddled. She says she "suffered from high levels of cortisol" as context for hitting her target weight, implying sermorelin addressed this. There is no strong evidence sermorelin directly lowers cortisol. Weight changes and lifestyle factors (she mentions reducing alcohol) are far more likely explanations. Attributing the weight result primarily to sermorelin here is a stretch.

The Andrew Huberman name-drop is also doing quiet work here. Huberman has discussed GHRH peptides on his podcast, but using his name as implicit scientific endorsement is not the same as citing a clinical trial. Worth noting the difference.

What should you actually know?

Sermorelin is a prescription compound in the US. It is not FDA-approved for anti-aging or body composition optimization in healthy adults. Its approved historical use was for diagnosing GH deficiency in children, and the original branded version (Geref) was withdrawn from the US market in 2008. What's prescribed today is compounded sermorelin, and compounded drugs are not FDA-reviewed for safety or efficacy. That does not make them dangerous, but it does mean the quality and dosing consistency vary by compounding pharmacy.

The creator is right that provider oversight matters. "You need a licensed provider and you need a structured plan" is genuinely good advice, not boilerplate. Self-administering peptides sourced from research chemical suppliers carries real risks including contamination, incorrect dosing, and no medical monitoring.

If you are considering sermorelin, baseline labs including IGF-1 levels are the standard starting point. A provider who doesn't order labs before prescribing should raise questions. And if a telehealth platform promises results without diagnostics, that is a red flag worth taking seriously.